FOXO1 and Hepatic fibrosis: Paeoniflorin could reduce cholestatic inflammation and liver fibrosis in the PBC mouse model by eliminating mtROS through the SIRT1/forkhead box O1 (FOXO1)/superoxide dismutase 2 (SOD2) signaling pathway, and thereby alleviate mitochondrial damage and inhibit NLRP3 inflammasome activation (185–187).